Cantargia doses first subject in expanded part of CAN10’s Phase I trial
Sweden-based Cantargia has commenced an expanded segment of the ongoing Phase I trial of its antibody, CAN10, with the first …
Post
-
-
Minghui reports positive topline data from trial of MH004 for atopic dermatitis
Minghui Pharmaceutical has reported positive topline outcomes from the randomised Phase III trial of its pan-Jak inhibitor, MH004 (tofacitinib etocomil) …
-
‘Pill-on-a-thread’ cancer screening trial commences with first patients
A pivotal investigator-led clinical trial for a new ‘pill-on-a-thread’ innovation for oesophageal cancer screening has welcomed its first patients, Cambridge …
-
Tryptamine Therapeutics completes dosing in obesity trial of TRP-8803
Tryptamine Therapeutics (Tryp) has announced the completion of subject dosing in a Phase Ib clinical trial of its psilocin-based intravenous …
-
Albus demonstrates device’s ability to detect asthma attacks in children
UK-based Albus Health (formerly BreathOx) has shared data revealing that its Albus Home AI-powered monitoring device can detect warning signs …
-
Takeda Canada co-sponsors grant to boost IBD clinical research
Takeda Canada has co-sponsored the Canadian Inflammatory Bowel Disease Research Consortium (CIRC) PIONEER Grant to boost clinical research efforts. The company …
-
New breast cancer combo sees success in New York trial
A new combination therapy designed for some of the most aggressive forms of breast cancer has shown promising results in …
-
Radiopharmaceutical trials face extra complexities due to nuclear red tape
The field of radiopharmaceuticals is growing rapidly, with a real buzz in oncology around emerging therapies. Radiopharmaceuticals are drugs that …
-
Galderma’s prurigo nodularis trial of nemolizumab meets endpoints
Galderma has reported that the randomised Phase III OLYMPIA 1 trial, which evaluated the nemolizumab monotherapy in adult subjects with …
-
Leading lead generation providers and technology solutions for the clinical trials industry
Leading lead generation providers and technology solutions for the clinical trials industry: Introduction The clinical trials sector is a critical component …
-
Telix Pharma doses first patient in Phase III PET carcinoma trial
Australian biotechnology company, Telix Pharmaceuticals, has announced that it has dosed the first patient as part of its Phase III …
-
UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment
UroGen Pharma has reported the outcomes from a long-term follow-up study of JELMYTO (mitomycin) for pyelocalyceal solution for treating low-grade, …
-
Sequana Medical’s DSR 2.0 outperforms traditional peritoneal dialysis solutions in study
Following positive data reported earlier this year from a Phase I/II trial, Sequana Medical has touted results from a study …
-
Shuttle Pharma announces glioblastoma trial expansion
Maryland-based drug discovery company Shuttle Pharma has announced the expansion of a Phase II trial of ropidoxuridine for glioblastoma patients …
-
Combatting Infectious Disease: Challenges and Opportunities for Pharma in the Green Transition
Climate change’s escalating impact is reshaping the infectious disease landscape in pervasive and profound ways. Rising temperatures are expanding the …
